Related references
Note: Only part of the references are listed.Empagliflozin Ameliorates Ouabain-Induced Na+ and Ca2+ Dysregulations in Ventricular Myocytes in an Na+-Dependent Manner
Xiaodong Peng et al.
CARDIOVASCULAR DRUGS AND THERAPY (2023)
Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells
Laween Uthman et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
Theresa A. McDonagh et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Ewald Kolesnik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism
Dou Huang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2022)
Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats
Moein Ala et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2022)
Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress
Panagiota Efstathia Nikolaou et al.
ANTIOXIDANTS & REDOX SIGNALING (2021)
Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis
Alex Ali Sayour et al.
DIABETOLOGIA (2021)
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
Zhaoyang Hu et al.
CARDIOVASCULAR DIABETOLOGY (2021)
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
Michael E. Nassif et al.
NATURE MEDICINE (2021)
Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure
Xuan Li et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins
Sin-Hee Park et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials
Gilson C. Fernandes et al.
HEART RHYTHM (2021)
Ketone Body Metabolism in the Ischemic Heart
Stephen C. Kolwicz
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus
Christina Kohlmorgen et al.
DIABETOLOGIA (2021)
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P. Curtain et al.
EUROPEAN HEART JOURNAL (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (vol 143, pg 326, 2021)
Packer
CIRCULATION (2021)
Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway
Entesar F. Amin et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2020)
Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway
Rania G. Abdel-latif et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Valentina Spigoni et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury
Sarayut Lahnwong et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
Wataru Shimizu et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels?
Coert J. Zuurbier
CARDIOVASCULAR DIABETOLOGY (2020)
Myocardial ischaemia-reperfusion injury and cardioprotection in perspective
Gerd Heusch
NATURE REVIEWS CARDIOLOGY (2020)
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
Donato Cappetta et al.
PHARMACOLOGICAL RESEARCH (2020)
Empagliflozin inhibits Na+/H+exchanger activity in human atrial cardiomyocytes
Maximilian Trum et al.
ESC HEART FAILURE (2020)
The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation
Caroline Honaiser Lescano et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
Alex Ali Sayour et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Prognostic Implications of Door-to-Balloon Time and Onset-to-Door Time on Mortality in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
Jonghanne Park et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA- REG OUTCOME Trial
David Fitchett et al.
CIRCULATION (2019)
Myocardial Ischemia Suppresses Ketone Body Utilization
Yuichiro Arima et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense
Julie L. Horton et al.
JCI INSIGHT (2019)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Borja Ibanez et al.
EUROPEAN HEART JOURNAL (2018)
Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury
Pongpan Tanajak et al.
JOURNAL OF ENDOCRINOLOGY (2018)
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMEA® randomised trial
Subodh Verma et al.
DIABETOLOGIA (2018)
SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
Robert M. Bell et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
Ioanna Andreadou et al.
FRONTIERS IN PHYSIOLOGY (2017)
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Ben A. Kappel et al.
CIRCULATION (2017)
Impact of high-fat, low-carbohydrate diet on myocardial substrate oxidation, insulin sensitivity, and cardiac function after ischemia-reperfusion
Jian Liu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2016)
Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure
Kenneth C. Bedi et al.
CIRCULATION (2016)
Myocardial Ischemia Lack of Coronary Blood Flow or Myocardial Oxygen Supply/Demand Imbalance?
Gerd Heusch
CIRCULATION RESEARCH (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Simon A. Hawley et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
Atsuo Tahara et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2016)
Relationship Between Infarct Size and Outcomes Following Primary PCI Patient-Level Analysis From 10 Randomized Trials
Gregg W. Stone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Pantelis A. Sarafidis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
Yoon-Kyung Chang et al.
PLOS ONE (2016)
Evolving Therapies for Myocardial Ischemia/Reperfusion Injury
Borja Ibáñez et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Glucocorticoid (dexamethasone)-induced metabolome changes in healthy males suggest prediction of response and side effects
Natalie Bordag et al.
SCIENTIFIC REPORTS (2015)
Cardioprotection: chances and challenges of its translation to the clinic
Gerd Heusch
LANCET (2013)
The basis of ischemia-reperfusion and myocardial protection
S. Benhabbouche et al.
ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION (2011)
Pathogenesis of Myocardial Ischemia-Reperfusion Injury and Rationale for Therapy
Aslan T. Turer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Elevated Cytosolic Na+ Increases Mitochondrial Formation of Reactive Oxygen Species in Failing Cardiac Myocytes
Michael Kohlhaas et al.
CIRCULATION (2010)
Regulation and pharmacology of the mitochondrial permeability transition pore
Dmitry B. Zorov et al.
CARDIOVASCULAR RESEARCH (2009)
Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts
Jinkun Xi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2009)
Heart Rate Reduction: Beneficial Effects in Heart Failure and Post-Infarcted Myocardium
Alain Berdeaux et al.
THERAPIE (2009)
Post-conditioning reduces infarct size in an open-chest porcine acute ischemia-reperfusion model
R. H. Lie et al.
ACTA ANAESTHESIOLOGICA SCANDINAVICA (2008)
Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: Results of the EXPEDITION study
Robert M. Mentzer et al.
ANNALS OF THORACIC SURGERY (2008)
Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials
Stewart R. Walsh et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2008)
Low carbohydrate diet decreases myocardial insulin signaling and increases susceptibility to myocardial ischemia
Peipei Wang et al.
LIFE SCIENCES (2008)
Effect of cyclosporine on reperfusion injury in acute myocardial infarction
Christophe Piot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oxidative stress is involved in the permeabilization of the inner membrane of brain mitochondria exposed to hypoxia/reoxygenation and low micromolar Ca2+
L Schild et al.
FEBS JOURNAL (2005)
Remote postconditioning - Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors
F Kerendi et al.
BASIC RESEARCH IN CARDIOLOGY (2005)
Protein kinase C spatially and temporally regulates gap junctional communication during human wound repair via phosphorylation of connexin43 on serine368
TS Richards et al.
JOURNAL OF CELL BIOLOGY (2004)
Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning
ZQ Zhao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the Arterial Revascularization Therapies Study (ARTS)
MA Costa et al.
CIRCULATION (2001)
Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication
PD Lampe et al.
JOURNAL OF CELL BIOLOGY (2000)
Share Paper
